Sukumar v. Nautilus, Inc., --- F.Supp.2d ----, 2011 WL
6325854 (W.D. Va.)
False marking is the gift that keeps on giving! The America Invents Act eliminated the patent
false marking qui tam provisions and added a competitive injury
requirement. The plaintiffs, who’d sued
before the AIA was passed, amended their complaint to allege bad faith and also
that they’d suffered a competitive injury as a result of Nautilus’s false
marking. They also added claims for
violation of California’s FAL and UCL as well as Washington consumer protection
law. Nautilus moved to dismiss the state
law claims on preemption grounds.
The court began by reviewing the elements of the state law
causes of action and concluding that they were all very similar in character,
and could be treated similarly for the limited purpose of assessing preemption.
There’s a general presumption against preemption. Consumer protection laws in particular have
historically been part of the states’ broad police powers and accorded special
deference unless there’s a clear direction from Congress.
The AIA contained no express preemption provision. Nautilus argued that Congress’s pervasive
regulation of patents created field preemption.
Courts have held that state RICO counterclaims are preempted when
identical in scope with an inequitable conduct defense, and that an abuse of
process claim based on proceedings before the PTO is also preempted as a
collateral intrusion on PTO procedures.
While it’s true that granting patents is exclusively a
matter of federal law, the Patent Act “has never been interpreted as wholly
upending the ability of the states to regulate anything tangentially related to
the issuance of a patent.” The Federal
Circuit has even recognized that a state unfair competition claim is not
subject to field preemption. However,
Nautilus argued that the AIA changed things enough to occupy the field. The court disagreed. Though the AIA did change false marking law,
that wasn’t the “major objective” of the law, which was focused on
first-to-file. The legislative history
on false marking focused on eliminating the qui tam remedy. There was no evidence that Congress “sought
to use the law to impose upon the traditional authority of the states to
regulate areas of consumer protection.”
The main question of patent law in the case at bar, for
preemption purposes, was whether the patent numbers affixed to Nautilus
products actually covered those products.
In light of the states’ historical role in consumer protection, the
court couldn’t find a clear and manifest purpose to occupy the field of false
marking law.
What about conflict preemption? Nautilus’s direct conflict argument was that,
because the state law claims have different elements and provide for different
remedies than Section 292, as amended, they must be preempted. “But this does not preemption make.” Concurrent regulation is pretty normal,
including in consumer protection. The
court analogized to fraud in connection with buying or selling commodities,
which is also regulated by both the US and California, albeit with different
elements and different remedies. In
other contexts, the Federal Circuit has identified different elements as a
reason not to preempt state law, because the state law didn’t involve patent-like
protection.
Nautilus argued that bringing forth state law unfair
competition claims would serve as an obstacle to Congress's intent in passing
the AIA, to wit “eliminat[ing] litigation brought by unrelated, private third
parties.” Congress aimed to address the
recent surge in false marking litigation, and thus allowing state law claims
would cut against that objective. But
Congress was concerned with the recent surge of qui tam cases brought on the
basis of expired patents, which wasn’t the case here. Moreover, plaintiffs couldn’t be deemed to be
“unrelated, private third parties”: they allege that they compete with Nautilus
and were deterred from designing certain rehabilitation equipment because of the
false marking. (The court commented that
“[i]t may very well be that a suit by a private plaintiff who does not allege
competitive injury does not survive the conflict preemption analysis.”)
Past precedent recognized two areas of preemption: (1) “federal
patent law bars the imposition of liability for conduct before the PTO unless
the plaintiff can show that the patentholder's conduct amounted to fraud or
rendered the patent application process a sham,” and (2) “federal patent law
bars the imposition of liability for publicizing a patent in the marketplace
unless the plaintiff can show that the patentholder acted in bad faith” (quoting
earlier decisions). The second scenario
was the most closely analogous to the case before the court. The allegations were that Nautilus placed
patent numbers on its products that didn’t cover those products. “At its core, Plaintiffs' false marking claim
is an attempt to hold Nautilus liable for ‘publicizing a patent in the
marketplace.’ Thus, under controlling precedent, the claim is preempted unless
Nautilus acted in bad faith.” Though the
state laws at issue didn’t have bad faith as an element, this was implied to escape
preemption. The complaint here
adequately alleged bad faith.
Finally, the court found that allowing state law claims here
wouldn’t interfere with the objectives of the patent laws (providing incentives
to invent, promoting disclosure, and protecting the public domain against state
laws propertizing it).
Separately, Nautilus argued that the Washington state law
claim should be dismissed because plaintiffs failed to meet that law’s “public
interest” requirement. Under Washington
law, an act or practice harms the public interest if it injured or had the
capacity to injure other persons. “It
seems obvious that the practice of falsely marking products which are sold to
the general public in the stream of commerce has the capacity to injure persons
other than [plaintiffs].” False marking
may dissuade potential competitors from entering the market, or deter
scientific research. That satisfied the
public interest element of the law.
No comments:
Post a Comment